An exploratory Phase I/II study of ANP-230 to evaluate the safety, efficacy and pharmacokinetics in patients with infantile episodic limb pain
Latest Information Update: 17 Jan 2024
At a glance
- Drugs DSP 2230 (Primary)
- Indications Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors AlphaNavi Pharma
- 17 May 2021 New trial record
- 11 May 2021 According to an AlphaNavi Pharma media release, this clinical development of ANP-230 was selected as one of the Cyclic Innovation for Clinical Empowerment (CiCLE) program under the application title: Study of a novel drug for familial episodic infantile limb pain syndrome, which is operated by the Japan Agency for Medical Research and Development (AMED).